Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University

Introduction: Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disease. BRAF V600E mutation is detected in nearly all classical HCL cases which offers the possibility of targeted therapy. Objective: The aim of our study was to assess the efficacy of low-dose vemurafenib as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferenczi, Kata, Nagy, Zsófia Flóra, Istenes, Ildikó, Eid, Hanna, Bödör, Csaba, Timár, Botond, Demeter, Judit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663343/
https://www.ncbi.nlm.nih.gov/pubmed/38025907
http://dx.doi.org/10.3389/pore.2023.1611378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663343/
https://www.ncbi.nlm.nih.gov/pubmed/38025907
http://dx.doi.org/10.3389/pore.2023.1611378

Ejemplares similares